1. Home
  2. MHH vs RLYB Comparison

MHH vs RLYB Comparison

Compare MHH & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mastech Digital Inc

MHH

Mastech Digital Inc

HOLD

Current Price

$7.85

Market Cap

91.1M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.65

Market Cap

86.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHH
RLYB
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.1M
86.6M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
MHH
RLYB
Price
$7.85
$16.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.6K
37.9K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$191,371,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$393.50
N/A
Revenue Growth
N/A
43.00
52 Week Low
$5.51
$0.40
52 Week High
$8.37
$17.57

Technical Indicators

Market Signals
Indicator
MHH
RLYB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MHH
RLYB

About MHH Mastech Digital Inc

Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: